You may have said it to more than one doctor. My labs are normal but I feel unwell. The most useful thing to know is that your labs were compared against a population average and that the population includes a great many people on their way to being sick. This page explains why normal is not the same as optimal, which markers a standard panel skips and what a 90-day Biomarker Audit adds.
- A standard panel answers whether you are diseased. It was never designed to tell you whether you are optimizing.
- The reference range is a 95 percent interval, which means the sick 5 percent and the struggling edge of the healthy 95 percent can produce identical results.
- Optimal ranges and population ranges are different questions and conflating them is how early metabolic drift gets missed for years.
- The Biomarker Audit measures the markers standard panels skip: Apolipoprotein B (ApoB), Lipoprotein (A), Hs-CRP and Fasting Insulin every 90 days.
Why normal is not the same as optimal
A laboratory reference range is a statistical statement about the middle 95 percent of people who take that test. It is not a statement about your ideal. That is why a fasting insulin in the upper part of the normal range can sit there quietly for a decade while insulin resistance develops and why a thyroid result can land inside the range while the person wearing that result has gained fifteen pounds and cannot lose it.
The gap between normal and optimal is where our Cardiometabolic Optimization Membership lives. The membership includes the Cardiometabolic Optimization Panel every 90 days, covering Apolipoprotein B (ApoB), Lipoprotein (A), Hs-CRP, Hemoglobin A1c (HbA1c), Lipid Panel, Standard, Fasting Insulin, TSH With Reflex To Free T4 and more. What that buys is not a fancier panel. It buys eyes. The same clinician reading your trend lines four times a year, watching the edge-of-range values move before they become diagnoses.
The markers that get called normal and are not
The most commonly missed markers are the ones standard panels skip or summarize.
ApoB is the count of atherogenic particles in your blood and many clinicians still read LDL cholesterol alone. You can have an LDL cholesterol that looks acceptable and an ApoB that tells a different story, which is why cardiovascular disease remains the leading cause of death in the United States despite decades of cholesterol screening. Lp(a) is a genetic risk marker that most people have never had measured at all and it does not move with diet or exercise, so it has to be known rather than managed.
hs-CRP is the inflammation marker that a standard panel often omits and fasting insulin is the one that shows insulin resistance a decade before glucose does. Thyroid: the standard panel is usually TSH alone and a TSH in range tells you nothing about free T3, free T4 or the antibodies that explain fatigue and weight that will not move. Hormones: a perimenopausal woman with an in-range day-21 estrogen can still be symptomatic and a man with a testosterone at the bottom of the normal range can carry every symptom of low testosterone while being told his labs are fine.
None of this is a criticism of standard panels, which are designed for a different purpose. They answer whether you are diseased. They were never designed to answer whether you are optimal and they were certainly not designed to be read by someone paid to spend more than eight minutes on the answer.
The American Diabetes Association's Standards of Care emphasize early identification of insulin resistance and prediabetes precisely because the window for intervention closes as disease establishes itself. The Biomarker Audit is built around that window rather than around a disease threshold.
What the 90-day audit actually does
The audit is not a bigger panel. It is a cadence.
First, it is comprehensive enough to catch what standard panels skip. Apolipoprotein B (ApoB), Lipoprotein (A), Hs-CRP, Hemoglobin A1c (HbA1c), Lipid Panel, Standard, Fasting Insulin, TSH With Reflex To Free T4 and more, drawn at any Quest patient service center. Second, it repeats. A single panel is a photograph. Four a year is a film and films are where trends become visible while they are still easy to act on. Third, it is connected to a decision. The same clinician who ordered the audit explains it, adjusts the protocol and answers the message you send in month seven about a symptom that arrived after your last draw.
The membership is $299 a month, month to month. The first two months ($598) are held on your card at sign-up and charged only once a clinician accepts you. The fee never rises with a prescription. Medication, when it is indicated, is prescribed to the pharmacy you choose at that pharmacy's own price, because we set nothing on the transaction and take nothing from it. The fee covers the doctor. The pharmacy covers the drug. The two never touch.
Who this is and is not for
If your goal is a tidy summary that says normal, the standard panel is cheaper and faster and you should keep it. If you are content to wait until a value crosses into disease range before acting, standard care is designed exactly for that and there is no shame in it.
If instead you want to know what your edge-of-range values are doing before they arrive anywhere, the eligibility check is the first step. It takes a few minutes and a clinician reviews every application. The $598 is a hold on your card, charged only once a clinician accepts you. If the clinician cannot accept you, the hold is released and you are never charged.
A reference range describes a population, not a person. The gap between the two is where symptoms live and where standard care stops looking.
Frequently Asked Questions
My labs are normal, so why do I feel unwell?
Because a reference range describes the middle 95 percent of tested people, not your ideal. Values at the edge of normal can carry real symptoms and a standard panel is not designed to answer the optimization question, only the disease question.
What is the difference between normal and optimal ranges?
A normal range is a population statistic. An optimal range is a clinical judgment about where a specific person's marker should sit for their goals and their risk. The two can differ by a wide margin, especially for fasting insulin, thyroid and hormones.
What markers does the Biomarker Audit include that a standard panel does not?
Apolipoprotein B (ApoB), Lipoprotein (A), Hs-CRP, Fasting Insulin and TSH With Reflex To Free T4. Free T4 is added by the lab only when the TSH result calls for it.
How often is the audit repeated?
Every 90 days, four times a year. Additional labs your clinician orders when there is a reason are billed by the lab at its own rates.
Does the $299 fee include the labs?
Yes. Four panels a year are included in the membership fee. Medication, when indicated, is billed by the pharmacy at its own price.
Is this a substitute for my annual physical?
No. The membership does not replace emergency care, hospital coverage or insurance for those events. It replaces the primary-care relationship, with a depth the standard visit was never priced to deliver.
Can I bring my old lab results?
Yes. Past results give your clinician a baseline and make the first audit more useful, so bring them to your intake.
Three cases where normal was the wrong answer
Because abstractions are easy to dismiss, three composite examples drawn from the patterns members describe, each one built from real marker behavior.
The first is the man whose fasting insulin sat in the normal range for nine years while his waistband climbed. His standard panel read fine, because glucose was still normal and the standard panel does not include insulin at all. His first Biomarker Audit put the Fasting Insulin near the top of the range and his clinician acted on it rather than waiting for the glucose to confirm what the insulin already knew.
The second is the woman whose TSH had been called normal through two pregnancies and a decade of fatigue, as one illustration of the pattern. TSH alone was the whole thyroid picture her doctors had. The audit added free T3, free T4 and the antibodies and the antibodies told the story: an autoimmune thyroid condition in its slow early phase, invisible to a TSH-only panel and unmistakable with one.
The third is the patient whose LDL cholesterol looked acceptable for years. His ApoB, never measured before the audit, told a different story about particle count and the protocol changed because the real number finally existed. Heart disease remains the leading cause of death in the United States and the particles driving it are the ones the standard panel does not count.
These are composites rather than case files and they are not proof. They are illustrations of the same mechanism. The gap between normal and optimal is where the standard panel stops looking and it is also where the next decade of most people's metabolic health is decided.
One last thing
A lab value is a data point, not a verdict. If you have been told you are normal while feeling unwell, the next useful step is not a bigger panel. It is a clinician who has time to read the one you already had and the quarterly cadence to see what it was hiding.
Related Guides
- Cardiometabolic Optimization: the definitive guide
- What a Biomarker Audit includes
- Why does no one listen to me at the doctor?
- Who the membership is and is not for
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/